Back to Awarded Treatment Trials
Awarded Trial: 02-STN-004
Grant ID
02-STN-004
Illness
Schizophrenia
Primary Drug/Intervention
Secretin
Primary Dosage
2 vials
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Lieberman
Sample Size
15
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
NOSIE, PANSS, CGI, CPT, RBS. RBANS. WAIS III, ABC, SDS
Results
In a preliminary trial of 15 patients with severe schizophrenia, this pancreatic hormone produced transient improvements in some patients. A follow-up study is desirable but difficult to do as the compound has limited availability.
Publication
N/A
Link
N/A
PI Name
Jeffrey Lieberman
Degree
MD
Center
N/A
Institution
University of North Carolina
Address
CB # 7160, 7025 Neurosciences Hospital
City or Town
Chapel Hill
State or Province
NC
Zip or Postal Code
27599
Country
USA
Email Address
jlieberman@unc.edu